PL3618827T3 - Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji - Google Patents

Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji

Info

Publication number
PL3618827T3
PL3618827T3 PL18794220.6T PL18794220T PL3618827T3 PL 3618827 T3 PL3618827 T3 PL 3618827T3 PL 18794220 T PL18794220 T PL 18794220T PL 3618827 T3 PL3618827 T3 PL 3618827T3
Authority
PL
Poland
Prior art keywords
tetrachlorobis
ruthenate
indazole
trans
compositions
Prior art date
Application number
PL18794220.6T
Other languages
English (en)
Polish (pl)
Inventor
Tomas Vojkovsky
Kevin Sill
Adam Carie
Original Assignee
Bold Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bold Therapeutics Inc. filed Critical Bold Therapeutics Inc.
Publication of PL3618827T3 publication Critical patent/PL3618827T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL18794220.6T 2017-05-05 2018-05-07 Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji PL3618827T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Publications (1)

Publication Number Publication Date
PL3618827T3 true PL3618827T3 (pl) 2024-01-22

Family

ID=64016742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18794220.6T PL3618827T3 (pl) 2017-05-05 2018-05-07 Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji

Country Status (11)

Country Link
US (5) US10611787B2 (https=)
EP (3) EP4245305B1 (https=)
JP (4) JP7183253B2 (https=)
CN (2) CN117462558A (https=)
AU (2) AU2018263965B2 (https=)
CA (1) CA3062369A1 (https=)
ES (1) ES2959891T3 (https=)
PL (1) PL3618827T3 (https=)
RU (1) RU2019138773A (https=)
SG (1) SG11201910043PA (https=)
WO (1) WO2018204930A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201910043PA (en) 2017-05-05 2019-11-28 Intezyne Technologies Inc Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof
WO2021108923A1 (en) * 2019-12-05 2021-06-10 Bold Therapeutics Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE10103565B4 (de) * 2001-01-26 2007-06-14 Faustus Forschungs Cie. Translational Cancer Research Gmbh Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
JP5296063B2 (ja) * 2007-06-11 2013-09-25 ニッキ ファーマ インク. ルテニウム錯体を製造する方法
WO2011161570A2 (en) * 2010-06-22 2011-12-29 Firmenich Sa Ruthenium based complexes
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
BR112015023568B8 (pt) 2013-03-15 2024-01-02 Ann Mcfarland Sherri Composto à base de metal como composto fotodinâmico
CN103601759B (zh) * 2013-10-18 2015-08-19 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌(iii)络合物的制备方法
EP3313392B1 (en) 2015-06-23 2020-09-16 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
SG11201910043PA (en) * 2017-05-05 2019-11-28 Intezyne Technologies Inc Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Also Published As

Publication number Publication date
JP2025123344A (ja) 2025-08-22
CA3062369A1 (en) 2018-11-08
US12415825B2 (en) 2025-09-16
JP2020518676A (ja) 2020-06-25
US20230357297A1 (en) 2023-11-09
AU2024203511A1 (en) 2024-06-20
AU2018263965B2 (en) 2024-02-29
SG11201910043PA (en) 2019-11-28
EP4245305A2 (en) 2023-09-20
JP2024045436A (ja) 2024-04-02
US20180327435A1 (en) 2018-11-15
WO2018204930A1 (en) 2018-11-08
JP7183253B2 (ja) 2022-12-05
ES2959891T3 (es) 2024-02-28
AU2024203511B2 (en) 2026-03-19
EP4245305B1 (en) 2025-10-08
EP4635503A3 (en) 2025-10-29
EP4245305C0 (en) 2025-10-08
EP3618827A4 (en) 2020-09-02
EP3618827A1 (en) 2020-03-11
JP7698083B2 (ja) 2025-06-24
US20260042792A1 (en) 2026-02-12
RU2019138773A3 (https=) 2022-02-01
JP7433402B2 (ja) 2024-02-19
EP3618827B1 (en) 2023-07-26
EP3618827C0 (en) 2023-07-26
JP2023016867A (ja) 2023-02-02
EP4245305A3 (en) 2023-10-04
US10611787B2 (en) 2020-04-07
EP4635503A2 (en) 2025-10-22
US20210277040A1 (en) 2021-09-09
US11040993B2 (en) 2021-06-22
US20200262855A1 (en) 2020-08-20
CN111372939B (zh) 2023-11-07
CN117462558A (zh) 2024-01-30
RU2019138773A (ru) 2021-06-08
CN111372939A (zh) 2020-07-03
US11739111B2 (en) 2023-08-29
AU2018263965A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
IL278829A (en) The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them
IL271604B (en) Fungicides
MX2020006595A (es) Oxadiazoles fungicidas.
WO2016011306A3 (en) Terminal modifications of polynucleotides
SG11202105578RA (en) Etching compositions
IL271891A (en) Stable preparations containing cannabinoids
ZA201808057B (en) Synthesis of indazoles
WO2015120062A3 (en) Therapeutic compounds and compositions
SG11202003348YA (en) Etching compositions
PL3618827T3 (pl) Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji
IL273259A (en) Production of pharmaceutical preparations
ZA202004532B (en) Compositions for the management of hyperglycemia and related conditions
EP3261437A4 (en) Fungicidal compounds and compositions
PT3448849T (pt) Síntese de indazóis
HUE072817T2 (hu) Gombaölõ készítmények
EP3318080A4 (en) User equipment adaptation of reporting triggers based on active set size
SG10201907729PA (en) Etching compositions
IL261384A (en) Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer
IL271892A (en) Stable preparations containing cannabinoids
EP3712133A4 (en) SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT
IL276410A (en) Pyrazole compounds and their preparation
IL272999A (en) A preparation for use in the treatment of eczema of the skin
GB2569412B (en) Chlorination of pyrazolinones
SG11202105114PA (en) Storage-stable form of 3-methylthiopropionaldehyde
HK40030313A (en) Glycan compositions and methods of use